BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab
ReutersFeb 3, 2025 12:49 PM
Feb 3 (Reuters) - AnaptysBio Inc ANAB.O:
VANDA PHARMACEUTICALS AND ANAPTYS ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR VANDA TO DEVELOP AND COMMERCIALIZE IMSIDOLIMAB, AN IL-36R ANTAGONIST
VANDA PHARMACEUTICALS INC: VANDA EXPECTS TO IMMEDIATELY BEGIN PREPARING BLA AND MAA APPLICATIONS FOR US AND EU
VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE $15 MILLION FROM VANDA, COMPRISED OF A $10 MILLION UPFRONT PAYMENT AND $5 MILLION FOR EXISTING DRUG SUPPLY
VANDA PHARMACEUTICALS INC: ANAPTYS TO RECEIVE A 10% ROYALTY ON GLOBAL NET SALES OF IMSIDOLIMAB
Source text: ID:nPn5brdDta
Further company coverage: ANAB.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
[Crypto IPO] Figure Technology Follows Circle and Bullish with Nasdaq Listing Plans
On August 18, U.S.-based blockchain lending firm Figure Technology Solutions Inc. publicly announced it has filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC), signaling its intent to go public on the Nasdaq Global Market under the ticker symbol FIGR.TradingKey
6 hours ago
Japan July CPI Preview: With Inflation Cooling, Will the Yen Still Rise?
TradingKey - Japan is set to release July inflation data on 22 August 2025. Market consensus predicts that the national Consumer Price Index (CPI) excluding fresh food will see its year-on-year increase slow from 3.3% in June to 3%. While forecasts for headline CPI and CPI excluding food and...TradingKey
9 hours ago
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
Thu, Aug 14
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,TradingKey
Wed, Jul 23
